Dysmenorrhea Treatment Market Research Report Information By Product Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), By Type of Treatment (Pain Relievers, Hormonal Therapy, And Surgery), By End-User (Hospitals & Clinics And Research Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 MARKET STRUCTURE

2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF DYSMENORRHEA AMONG ADOLESCENT GIRLS

4.2.2 INCREASING CASES OF MENSTRUAL CRAMPS DUE TO GENETIC DISORDERS

4.3 RESTRAINTS

4.3.1 CONCERNS PERTAINING TO SIDE EFFECTS

4.3.2 HIGH AVAILABILITY OF ALTERNATIVE PRODUCTS

4.4 OPPORTUNITIES

4.4.1 THE EMERGENCE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR DYSMENORRHEA TREATMENT

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION, MARKETING, & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 COVID-19 IMPACT ANALYSIS

5.3.1 IMPACT ON WOMEN'S HEALTH

5.3.2 IMPACT ON TREATMENT

6 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE

6.1 OVERVIEW

6.2 PRIMARY DYSMENORRHEA

6.3 SECONDARY DYSMENORRHEA

7 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT

7.1 OVERVIEW

7.2 PAIN RELIEVERS

7.3 HORMONAL THERAPY

7.4 SURGERY

7.5 OTHERS

8 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS & CLINICS

8.3 RESEARCH CENTRES

8.4 OTHERS

9 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY REGION

9.1 INTRODUCTION

9.2 AMERICAS

9.2.1 NORTH AMERICA

9.2.1.1 US

9.2.1.2 CANADA

9.2.2 LATIN AMERICA

9.3 EUROPE

9.3.1 WESTERN EUROPE

9.3.1.1 GERMANY

9.3.1.2 FRANCE

9.3.1.3 UK

9.3.1.4 ITALY

9.3.1.5 SPAIN

9.3.1.6 REST OF WESTERN EUROPE

9.3.2 EASTERN EUROPE

9.4 ASIA PACIFIC

9.4.1 CHINA

9.4.2 INDIA

9.4.3 JAPAN

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA PACIFIC

9.5 MIDDLE EAST & AFRICA

9.5.1 MIDDLE EAST

9.5.2 AFRICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 MERGER/ACQUISITION

10.7 FINANCIAL MATRIX

10.7.1 SALES (USD MILLION), 2020

10.7.2 R&D EXPENDITURE (USD MILLION), 2020

11 COMPANY PROFILES

11.1 NOVARTIS AG

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS/SERVICES OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 PFIZER, INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS/SERVICES OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 RECKITT BENCKISER GROUP PLC.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS/SERVICES OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 SANOFI S.A.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS/SERVICES OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 VIATRIS INC.

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS/SERVICES OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 JOHNSON & JOHNSON SERVICES INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS/SERVICES OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 GLAXOSMITHKLINE PLC

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS/SERVICES OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 F. HOFFMANN-LA ROCHE LTD

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS/SERVICES OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 BAYER AG

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS/SERVICES OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 SWOT ANALYSIS

11.9.6 KEY STRATEGIES

11.10 FOCUS CONSUMER HEALTHCARE, LLC

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS/SERVICES OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 SWOT ANALYSIS

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS USED DURING MENSTRUATION IN THE TREATMENT OF PRIMARY DYSMENORRHEA IN ADOLESCENTS AND YOUNG ADULTS

TABLE 3 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 4 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR PRIMARY DYSMENORRHEA, BY REGION, 2022–2030 (USD MILLION)

TABLE 5 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR SECONDARY DYSMENORRHEA, BY REGION, 2022–2030 (USD MILLION)

TABLE 6 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 7 GLOBAL: DYSMENORRHEA TREATMENT MARKET FOR PAIN RELIEVERS, BY REGION, 2022–2030 (USD MILLION)

TABLE 8 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR HORMONAL THERAPY, BY REGION, 2022–2030 (USD MILLION)

TABLE 9 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR SURGERY, BY REGION, 2022–2030 (USD MILLION)

TABLE 10 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR OTHERS, BY REGION, 2022–2030 (USD MILLION)

TABLE 11 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 12 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION)

TABLE 13 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR RESEARCH CENTRES, BY REGION, 2022–2030 (USD MILLION)

TABLE 14 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR OTHERS, BY REGION, 2022–2030 (USD MILLION)

TABLE 15 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY REGION, 2022–2030 (USD MILLION)

TABLE 16 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION)

TABLE 17 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 18 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 19 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 20 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 22 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 24 US: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 25 US: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 26 US: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 27 CANADA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 28 CANADA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 29 CANADA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 30 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 31 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 32 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 33 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY REGION, 2022–2030 (USD MILLION)

TABLE 34 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 35 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 36 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 37 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION)

TABLE 38 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 39 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 40 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 41 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 42 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 43 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 44 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 45 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 46 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 47 UK: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 48 UK: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 49 UK: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 50 ITALY: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 51 ITALY: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 52 ITALY: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 53 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 54 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 55 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 56 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 57 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 58 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 59 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 60 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 61 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 62 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION)

TABLE 63 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 64 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 65 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 66 CHINA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 67 CHINA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 68 CHINA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 69 INDIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 70 INDIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 71 INDIA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 72 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 73 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 74 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 75 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 76 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 77 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 78 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 79 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 80 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 81 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 82 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 83 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 84 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION)

TABLE 85 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 86 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 87 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 88 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 89 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 90 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 91 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION)

TABLE 92 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2022–2030 (USD MILLION)

TABLE 93 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION)

TABLE 94 MAJOR PLAYERS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

TABLE 95 MOST ACTIVE PLAYER IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

TABLE 96 MERGER/ACQUISITION

TABLE 97 NOVARTIS AG: PRODUCTS/SERVICES OFFERED

TABLE 98 PFIZER, INC.: PRODUCTS/SERVICES OFFERED

TABLE 99 RECKITT BENCKISER GROUP PLC.: PRODUCTS/SERVICES OFFERED

TABLE 100 RECKITT BENCKISER GROUP PLC.: KEY DEVELOPMENTS

TABLE 101 SANOFI S.A.: PRODUCTS/SERVICES OFFERED

TABLE 102 SANOFI S.A.: KEY DEVELOPMENTS

TABLE 103 VIATRIS INC.: PRODUCTS/SERVICES OFFERED

TABLE 104 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED

TABLE 105 GLAXOSMITH KLINE PLC: PRODUCTS/SERVICES OFFERED

TABLE 106 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED

TABLE 107 BAYER AG: PRODUCTS/SERVICES OFFERED

TABLE 108 BAYER AG: KEY DEVELOPMENTS

TABLE 109 FOCUS CONSUMER HEALTHCARE, LLC: PRODUCTS/SERVICES OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL DYSMENORRHEA TREATMENT MARKET STRUCTURE

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 3 MARKET DYNAMICS: GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 4 DRIVERS: IMPACT ANALYSIS

FIGURE 5 RESTRAINTS: IMPACT ANALYSIS

FIGURE 6 VALUE CHAIN ANALYSIS OF THE GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 8 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2020 & 2030 (USD MILLION)

FIGURE 9 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2020 & 2030 (USD MILLION)

FIGURE 10 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2020 & 2030 (USD MILLION)

FIGURE 11 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY REGION 2020 & 2030 (USD MILLION)

FIGURE 12 GLOBAL: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020

FIGURE 13 AMERICAS: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020

FIGURE 14 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020

FIGURE 15 EUROPE: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020

FIGURE 16 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020

FIGURE 17 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020

FIGURE 18 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 21 GLOBAL DYSMENORRHEA TREATMENT MARKET: COMPETITIVE LANDSCAPE

FIGURE 22 SALES (USD MILLION), 2020

FIGURE 23 R&D EXPENDITURE (USD MILLION), 2020

FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 NOVARTIS AG: SWOT ANALYSIS

FIGURE 26 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 PFIZER, INC.: SWOT ANALYSIS

FIGURE 28 RECKITT BENCKISER GROUP PLC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 RECKITT BENCKISER GROUP PLC.: SWOT ANALYSIS

FIGURE 30 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 SANOFI S.A.: SWOT ANALYSIS

FIGURE 32 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 VIATRIS INC.: SWOT ANALYSIS

FIGURE 34 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS

FIGURE 36 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS

FIGURE 40 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 41 BAYER AG: SWOT ANALYSIS

FIGURE 42 FOCUS CONSUMER HEALTHCARE, LLC: SWOT ANALYSIS